Re-assessment of the Actual Benefit of all medicines indicated for menopausal hormone replacement therapy at the request of the Committee, pursuant to Article R-163-21 of the French Social Security Code and Change in the conditions for inclusion following amendments to the SPC Renewal of inclusion
-
Clinical Benefit
Substantial
The actual benefit of the proprietary medicinal products ESTRAPATCH 40 μg/24 h, 60 μg/24 h and 80 μg/24 h in hormone replacement therapy (HRT) for symptoms of oestrogen deficiency in menopausal women remains substantial in patients for whom climacteric disorders are described as troublesome enough to impair their quality of life when these proprietary medicinal products are used as per the Committee's recommendations.
Listen
